glp 1 thyroid cancer risk Glucagon-like peptide receptor agonist use and of cancer: Scandinavian cohort study Clayman - Do GLP-1 Weight-Loss

Ozempic is designed for managing type 2 diabetes, while Wegovy is specifically approved for weight loss

SCFAs-including acetate, propionate, and butyrate-activate GPR41 and GPR43 receptors expressed on myocytes and engage metabolic signaling pathways such as AMP-activated protein kinase (AMPK) and peroxisome proliferator-activated receptor (PPAR) networks, thereby promoting mitochondrial biogenesis, fatty acid oxidation, and protein synthesis [151-153]

The beyond-use date indicates the last day the medication should be used to ensure its safety and effectiveness

u tin la chn cc thng hiu uy tn, c nh gi cao trn th trng